GlassScriptPhysician profile
Gregory G Papadeas
NPI 1730181405
$5,611.91
in general payments reported to CMS, 2019-2025
28 companies · $1,105 in 2025
The $1,105 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $786 · 2020: $392 · 2021: $560 · 2022: $693 · 2023: $1,041 · 2024: $1,034 · 2025: $1,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,082 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,081.98 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,200.46 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $610.80 | 2020-2025 | Levulan Kerastick, Winlevi, Blu-U |
| Genzyme Corporation | $409.73 | 2021-2025 | |
| Janssen Biotech, INC. | $350.87 | 2019-2025 | Tremfya, Stelara, Simponi |
| E.R. Squibb & Sons, L.L.C. | $323.30 | 2022-2024 | Sotyktu |
| Lilly USA, LLC | $320.36 | 2019-2024 | Olumiant, Taltz |
| Almirall LLC | $303.32 | 2019-2025 | Seysara |
| Amgen INC. | $285.08 | 2019-2025 | Otezla, Otezla |
| Leo Pharma INC. | $266.65 | 2019-2025 | Adbry |
| Pfizer INC. | $256.90 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $249.95 | 2024-2025 | Dupixent, Libtayo |
| Ucb, INC. | $221.61 | 2019-2025 | Bimzelx, Cimzia |
| Allergan, INC. | $145.72 | 2020-2022 | |
| Dermavant Sciences, INC. | $132.42 | 2023-2024 | Vtama |
| Strata Skin Sciences, INC. | $100.52 | 2022-2024 | Xtrac |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $92.56 | 2019-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Incyte Corporation | $62.88 | 2021-2024 | Opzelura |
| Galderma Laboratories, L.P. | $61.43 | 2023-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $45.91 | 2019-2021 | |
| Helsinn Therapeutics (U.S.), INC. | $30.14 | 2019-2022 | |
| Verrica Pharmaceuticals INC. | $26.80 | 2023 | Ycanth |
| Mallinckrodt Hospital Products INC. | $24.54 | 2024 | Acthar |
| Genentech USA, INC. | $17.97 | 2021 | |
| Aclaris Therapeutics, INC. | $17.16 | 2019 | |
| Neurocrine Biosciences, INC. | $17.04 | 2025 | |
| Arcutis Biotherapeutics, INC. | $16.79 | 2025 | Zoryve |
| Dusa Pharmaceuticals, INC. | $14.97 | 2019 | |
| Organon LLC | $6.03 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Papadeas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.